A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Vitreoretinal Disease Clinical Trial

Official title:

A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06294613
• Other study ID #: CIV-23-07-043672
• Status: Recruiting
• Phase: N/A
• Start date: February 8, 2024
• Est. completion date: July 2024

Study information

• Verified date: February 2024
• Source: Acusurgical
• Contact: Charlene Braun
• Phone: +33663334352
• Email: charlene.braun[@]acusurgical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, interventional, open-label, non-controlled, monocentric study in Belgium of Luca, of up to 7 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker.

Only one eye per subject can be enrolled.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 7
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Given written Informed Consent by subject,

• Males or females aged 18 - 85 years, pseudophakic or aphakic,

• Willing and able to comply with the schedule for follow-up visits,

• Requiring vitrectomy under general anesthesia (conditions include vitreous hemorrhage treatment (with potential clinical conditions including diabetic retinopathy, vascular occlusion, adverse effect of anticoagulant therapy), macular pucker),

• BCDVA <7/10,

• Deemed fit for robotic surgery per surgeons' assessment, including ability to undergone general anesthesia,

• Beneficiary of health insurance.

Exclusion Criteria:

• Uncontrolled systemic disease that could increase the operative risk or confound the outcome (autoimmune disease, uncontrolled hypertension, lung and heart disease impairing respiratory function, or any other medical condition as deemed by the Clinical Investigator),

• BMI (kg/m²) > 30,

• Axial length <22 or >26 mm per ocular biometry, inclusive,

• Presence of clinically significant ocular inflammation or infection within 30 days of Preop Visit, such as CME, uveitis, etc.,

• Ocular condition, that in the opinion of the Clinical Investigator, may predispose for future complications or confound visual acuity results, including profound amblyopia (<1/10) or strabismus,

• Ocular condition presenting associated pathology likely to require additional surgical manipulation, such as known need for membrane peeling, or retinal neovacular formation to be cut,

• Already vitrectomized on the study eye,

• Presenting retinal detachment or retinal tear,

• History of ocular traumatism; post-traumatic vitreous hemorrhage,

• Corneal scar preventing clear visualization of fundus,

• Any associated ocular pathology or ocular degenerative disorder that is uncontrolled such as glaucoma with clinical visual defect or IOP not controlled by medical treatment, uveitis, optic nerve damage,

• Subjects without light perception,

• Subject participating in other clinical studies,

• Subject being dependent on the Sponsor or Clinical Investigator,

• Pregnant or lactating women, based on self-declaration.

Related Conditions & MeSH terms

• Vitreoretinal Disease

Intervention

Device:
• vitreoretinal surgery
Patients undergoing vitreoretinal surgery

Locations

Country	Name	City	State
Belgium	UZ Gent	Gent	East Flanders

Sponsors (1)

Lead Sponsor	Collaborator
Acusurgical

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Outcome	incidence and severity of investigational device-related (definitely or probably) adverse events, for all subjects treated with the study device (Safety Population).	3 Months